Stroke Due to Cerebral Vasculitis in a Patient with Relentless Placoid Chorioretinitis.

Purpose: To report the first case of stroke in a patient with relentless placoid chorioretinitis.

Methods: Observational case report.

Results: A 20-year-old female with newly diagnosed relentless placoid chorioretinitis was urgently evaluated for unilateral paresthesias.

Intravitreal Versus Subretinal Tissue Plasminogen Activator Injection for Submacular Hemorrhage.

Background And Objective: The objective of this study was to compare visual acuity outcomes between the following procedures used to treat submacular hemorrhages: pneumatic displacement followed by intravitreal tissue plasminogen activator (tPA) if needed (pneumatic ± tPA) and pars plana vitrectomy (PPV) with subretinal tPA (PPV + tPA).

Patients And Methods: This is a retrospective chart review of submacular hemorrhages treated with either pneumatic ± tPA or PPV + tPA.

Results: Eighteen patients had pneumatic ± tPA, and 14 patients had PPV + tPA.

Rates of visual acuity change in patients receiving hyperbaric oxygen in monoplace and multiplace chambers.

Introduction: Changes in visual acuity are a known side effect of hyperbaric oxygen (HBO₂). We conducted a quality improvement initiative to better quantify visual change risk and to identify possible risk factors.

Methods: Vision was checked weekly in a clinical HBO₂ population by Snellen eye chart.

EZOGABINE (POTIGA) MACULOPATHY.

Purpose: To present a case of partially reversible retinal toxicity related to a newer epilepsy medication, ezogabine (Potiga).

Methods: Case report with multimodal imaging.

Patient: A patient presented 9 months after starting ezogabine for a screening eye examination with new retinal pigment abnormalities in the maculas of both eyes.

Effects of positive airway pressure on patients with obstructive sleep apnea during acute ascent to altitude.

Rationale: In acute ascent to altitude, untreated obstructive sleep apnea (OSA) is often replaced with central sleep apnea (CSA). In patients with obstructive sleep apnea who travel to altitude, it is unknown whether their home positive airway pressure (PAP) settings are sufficient to treat their obstructive sleep apnea, or altitude-associated central sleep apnea.

Methods: Ten participants with positive airway pressure-treated obstructive sleep apnea, who reside at 1,320 m altitude, underwent polysomnography on their home positive airway pressure settings at 1,320 m and at a simulated altitude of 2,750 m in a hypobaric chamber.